EUVIMEDEUVIMED entdecken
Vergleichsstudie

Neoadjuvant chemoimmunotherapy cycles in locally advanced Esophageal squamous cell carcinoma: a retrospective comparison of three versus two cycles

Aizemaiti Rusidanmu, Zibunisha Yakufu, Kun Zhou, Xing Xin Zhu, Di Fan Zheng, Zheng Liang Tu, Hai Ping Jiang, Rong Yang, Kan Feng Liu, Hui Fang Zhang, Hao Gang Yu, Shreya Singh und 2 weitere

Diseases of the Esophagus · 01.11.2025 · 38 (6)

DOI: 10.1093/dote/doaf101 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diseases of the Esophagus, online erschienen am 19.11.2025. Verfasst von Aizemaiti Rusidanmu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Esophageal squamous cell carcinoma is a major global health challenge in its locally advanced stages. Neoadjuvant chemoimmunotherapy aims to downstage tumors before surgery, but the optimal number of cycles remains uncertain. We performed a single-institution retrospective study of 208 consecutive patients with resectable, locally advanced esophageal squamous cell carcinoma treated between March 2020 and April 2024. Patients received either two (n = 84) or three (n = 124) cycles of platinum-based chemotherapy plus a programmed death-1 inhibitor, followed by esophagectomy without planned radiotherapy. Primary outcomes were pathologic complete response and disease-free survival; safety and clinical-to-pathologic downstaging were prespecified secondary end points. Three cycles yielded higher objective response (75.0% vs. 60.7%) and a higher pathologic complete response of the primary tumor (27.4% vs. 11.9%) than two cycles. Disease-free survival favored three cycles (hazard ratio, 0.52). Treatment-related adverse events occurred more often with three cycles, driven mainly by bone-marrow suppression (32.3% vs. 11.9%) but were generally manageable and compatible with timely surgery. Overall survival did not differ within the current median follow-up of 21 months. This retrospective analysis suggests that three cycles of neoadjuvant chemoimmunotherapy may provide greater tumor response and improved disease-free survival compared with two cycles in operable esophageal squamous cell carcinoma, with acceptable toxicity. However, neoadjuvant chemoradiation—which typically achieves higher pathologic complete response rates—remains the standard of care. Longer follow-up and prospective, stratified trials are needed to validate these findings and to define the role of a radiation-free strategy in appropriately selected patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyEsophageal Squamous Cell CarcinomaEsophageal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansRetrospective StudiesFemaleMaleMiddle AgedAgedEsophagectomyTreatment OutcomeDisease-Free SurvivalImmune Checkpoint InhibitorsNeoplasm StagingAdult

Stichwörter der Autor:innen

antineoplastic combined chemotherapy protocolcarcinomaesophageal neoplasmimmunotherapyneoadjuvant therapysquamous cell

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Neonatology, American-Sino Women's and Children's Hospital, Shanghai, China.
  • Department of Thoracic Surgery, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Oncology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Radiology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Nuclear Medicine, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.

Zitieren

APA

Rusidanmu, A., Yakufu, Z., Zhou, K., Zhu, X. X., Zheng, D. F., Tu, Z. L., Jiang, H. P., Yang, R., Liu, K. F., Zhang, H. F., Gang Yu, H., Singh, S., Chin, D., & Ye, P. (2025). Neoadjuvant chemoimmunotherapy cycles in locally advanced Esophageal squamous cell carcinoma: a retrospective comparison of three versus two cycles. Diseases of the Esophagus, 38(6). https://doi.org/10.1093/dote/doaf101

Vancouver

Rusidanmu A, Yakufu Z, Zhou K, Zhu XX, Zheng DF, Tu ZL, et al. Neoadjuvant chemoimmunotherapy cycles in locally advanced Esophageal squamous cell carcinoma: a retrospective comparison of three versus two cycles. Diseases of the Esophagus. 2025;38(6). doi:10.1093/dote/doaf101

BibTeX
@article{Rusidanmu2025,
  author = {Rusidanmu, Aizemaiti and Yakufu, Zibunisha and Zhou, Kun and Zhu, Xing Xin and Zheng, Di Fan and Tu, Zheng Liang and Jiang, Hai Ping and Yang, Rong and Liu, Kan Feng and Zhang, Hui Fang and Gang Yu, Hao and Singh, Shreya and Chin, Deanna and Ye, Peng},
  title = {Neoadjuvant chemoimmunotherapy cycles in locally advanced Esophageal squamous cell carcinoma: a retrospective comparison of three versus two cycles},
  journal = {Diseases of the Esophagus},
  year = {2025},
  volume = {38},
  number = {6},
  doi = {10.1093/dote/doaf101}
}
Kostenlos starten →